Brief: Appili Therapeutics Submits CTA With Health Canada
11/05/2020 13:45
May 11 (Reuters) - Appili Therapeutics Inc APLI.V :
* APPILI THERAPEUTICS SUBMITS CTA WITH HEALTH CANADA TO
SPONSOR
PROPHYLACTIC PHASE 2 CLINICAL TRIAL EVALUATING FUJIFILM TOYAMA
CHEMICAL’S FAVIPIRAVIR AS A PREVENTATIVE MEASURE AGAINST
COVID-19 IN CANADIAN LONG-TERM CARE FACILITIES
* APPILI THERAPEUTICS INC - CLINICAL PROGRAM DESIGNED TO
ASSESS
USE OF FAVIPIRAVIR FOR COVID-19 AS PROPHYLAXIS FOR OUTBREAK
CONTROL
Source text for Eikon: ID:nBw7M1H0Ha
Further company coverage: APLI.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez